5 sources·Health

Study Reveals Low Rates of Gender-Affirming Medications Among U.S. Adolescents

A new study shows fewer than 1 in 1,000 U.S. adolescents receive gender-affirming treatments, challenging prevalent political narratives.

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).
Mostly Reliable
The underlying sources are generally reliable but sometimes include opinion, propaganda, or minor inaccuracies.
Balanced
The underlying sources are either a balanced mix of left and right or primarily centrist.

No highlights available for this story.

Updated: Jan 6th, 2025, 3:29 PM ET

Summary

A summary of the key points of this story verified across multiple sources.

A recent JAMA Pediatrics study found that fewer than 0.1% of U.S. adolescents with commercial insurance received gender-affirming medications from 2018 to 2022. Analyzing data from over 5 million patients, the study revealed only 926 adolescents were prescribed puberty blockers, and 1,927 received hormones, primarily among assigned female at birth youth. The findings challenge often exaggerated claims about transgender youth healthcare amidst ongoing legal debates and state-level bans. Major medical organizations endorse these treatments as necessary, but access remains limited, prompting calls for a more accurate public understanding of gender-affirming care.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.

Study Reveals Low Rates of Gender-Affirming Medications Among U.S. Adolescents - Pano News